Sekisui XenoTech hires in record numbers, expects 10% growth

By Melissa Fassbender

- Last updated on GMT

Sekisui XenoTech headquarters in Kansas City, KS. (Image: Sekisui XenoTech)
Sekisui XenoTech headquarters in Kansas City, KS. (Image: Sekisui XenoTech)

Related tags North america Contract research organization

Sekisui XenoTech hired in record numbers in 2017 as it anticipates 10% or higher growth over the next couple of years fueled by demand for drug-drug interaction studies.

2017 tied 2011 for the company’s second-highest number of hires in a single year, according to the global contract research organization (CRO).

In addition to hiring new employees, the company has also been focusing on ongoing training and career advancement for its existing staff, as it experiences an increasing demand for its products and services.

Geographically, the company has seen the most sales growth over the last year in North America – a trend which it expects to continue in 2018, Toshinari Ohara, PhD, CEO of Sekisui XenoTech told

We have seen strong demand across all of our research service areas, although a particularly high percentage of recent inquiries have focused on our drug-drug interaction expertise following the new FDA and PMDA DDI guidance documents​,” he explained.

Ohara also said the company has seen strong demand across its in vitro​ test system offerings.

In particular, requests for our CryostaX hepatocytes increased following the recently awarded patent​, as have orders for our Research Biobank disease-defined liver tissue preparations because of their value for NASH research​,” he added.

Darren Warren, PhD, who was appointed as the company’s new chief operating officer (COO) in October, told us the company is anticipating 10% or higher growth “for at least the next couple of years​.”

Considering our long-standing DDI expertise and the FDA, PMDA and upcoming EMA guidance, drug-drug interaction studies and consulting will likely remain in particularly high demand​,” he added.

Warren said the company will also be announcing new test system products following demand for both legacy and recently introduced products in addition to custom preparation requests.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more